How to buy Amicus Therapeutics stock

Amicus Therapeutics, Inc is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Amicus Therapeutics employs 483 staff and has a trailing 12-month revenue of around 0.00.

Amicus Therapeutics share price

Use our graph to track the performance of FOLD stocks over time.

Amicus Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$8.83 - $25.39
50-day moving average	$9.93
200-day moving average	$17.07
Wall St. target price	$18.14
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.13

Buy Amicus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Amicus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Amicus Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Amicus Therapeutics financials

Revenue TTM	$260.9 million
Gross profit TTM	$229.8 million
Return on assets TTM	-17.55%
Return on equity TTM	-72.59%
Profit margin	-106.12%
Book value	$1.09
Market capitalisation	$2.7 billion

TTM: trailing 12 months

Shorting Amicus Therapeutics shares

There are currently 32.0 million Amicus Therapeutics shares held short by investors – that's known as Amicus Therapeutics's "short interest". This figure is 3.3% down from 33.1 million last month.

There are a few different ways that this level of interest in shorting Amicus Therapeutics shares can be evaluated.

Amicus Therapeutics's "short interest ratio" (SIR)

Amicus Therapeutics's "short interest ratio" (SIR) is the quantity of Amicus Therapeutics shares currently shorted divided by the average quantity of Amicus Therapeutics shares traded daily (recently around 3.2 million). Amicus Therapeutics's SIR currently stands at 9.92. In other words for every 100,000 Amicus Therapeutics shares traded daily on the market, roughly 9920 shares are currently held short.

However Amicus Therapeutics's short interest can also be evaluated against the total number of Amicus Therapeutics shares, or, against the total number of tradable Amicus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amicus Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Amicus Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.122% of the tradable shares (for every 100,000 tradable Amicus Therapeutics shares, roughly 122 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Amicus Therapeutics.

Find out more about how you can short Amicus Therapeutics stock.

Amicus Therapeutics share dividends

We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.

Amicus Therapeutics share price volatility

Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $8.83 up to $25.39. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 1.1748. This would suggest that Amicus Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Amicus Therapeutics overview

Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Frequently asked questions

• What percentage of Amicus Therapeutics is owned by insiders or institutions?

  Currently 0.487% of Amicus Therapeutics shares are held by insiders and 105.852% by institutions.

• How many people work for Amicus Therapeutics?

  Latest data suggests 483 work at Amicus Therapeutics.

• When does the fiscal year end for Amicus Therapeutics?

  Amicus Therapeutics's fiscal year ends in December.

• Where is Amicus Therapeutics based?

  Amicus Therapeutics's address is: 3675 Market Street, Philadelphia, PA, United States, 19104

• What is Amicus Therapeutics's ISIN number?

  Amicus Therapeutics's international securities identification number is: US03152W1099

• What is Amicus Therapeutics's CUSIP number?

  Amicus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03152W109